Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Drugs acting on SUR1 to treat CNS ischemia and trauma.

Simard JM, Woo SK, Bhatta S, Gerzanich V.

Curr Opin Pharmacol. 2008 Feb;8(1):42-9. Epub 2007 Nov 26.

2.

Does inhibiting Sur1 complement rt-PA in cerebral ischemia?

Simard JM, Geng Z, Silver FL, Sheth KN, Kimberly WT, Stern BJ, Colucci M, Gerzanich V.

Ann N Y Acad Sci. 2012 Sep;1268:95-107. doi: 10.1111/j.1749-6632.2012.06705.x. Review.

3.

Sulfonylurea receptor 1 in central nervous system injury: a focused review.

Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V.

J Cereb Blood Flow Metab. 2012 Sep;32(9):1699-717. doi: 10.1038/jcbfm.2012.91. Epub 2012 Jun 20. Review.

4.

[Molecular and functional diversity of ATP-sensitive K+ channels: the pathophysiological roles and potential drug targets].

Nakaya H, Miki T, Seino S, Yamada K, Inagaki N, Suzuki M, Sato T, Yamada M, Matsushita K, Kurachi Y, Arita M.

Nihon Yakurigaku Zasshi. 2003 Sep;122(3):243-50. Review. Japanese.

PMID:
12939542
5.

Non-selective cation channels, transient receptor potential channels and ischemic stroke.

Simard JM, Tarasov KV, Gerzanich V.

Biochim Biophys Acta. 2007 Aug;1772(8):947-57. Epub 2007 Mar 19. Review.

6.
7.

[ATP-sensitive potassium channel and its cardiovascular protection effects].

Zhang RY, Jin HF, Tang CS, DU JB.

Beijing Da Xue Xue Bao. 2009 Apr 18;41(2):245-8. Review. Chinese.

8.

Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4.

Simard JM, Kahle KT, Gerzanich V.

J Neurosurg. 2010 Sep;113(3):622-9. doi: 10.3171/2009.11.JNS081052. Review.

9.

Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.

Nagashima K, Takahashi A, Ikeda H, Hamasaki A, Kuwamura N, Yamada Y, Seino Y.

Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S75-8. Review.

PMID:
15563985
10.

Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury.

Lefer DJ, Nichols CG, Coetzee WA.

Trends Cardiovasc Med. 2009 Feb;19(2):61-7. doi: 10.1016/j.tcm.2009.04.008. Review.

11.

A view of sur/KIR6.X, KATP channels.

Babenko AP, Aguilar-Bryan L, Bryan J.

Annu Rev Physiol. 1998;60:667-87. Review.

PMID:
9558481
12.

Human K(ATP) channelopathies: diseases of metabolic homeostasis.

Olson TM, Terzic A.

Pflugers Arch. 2010 Jul;460(2):295-306. doi: 10.1007/s00424-009-0771-y. Epub 2009 Dec 24. Review.

13.

KATP channel openers: structure-activity relationships and therapeutic potential.

Mannhold R.

Med Res Rev. 2004 Mar;24(2):213-66. Review.

PMID:
14705169
14.
16.

Glibenclamide for the treatment of ischemic and hemorrhagic stroke.

Caffes N, Kurland DB, Gerzanich V, Simard JM.

Int J Mol Sci. 2015 Mar 4;16(3):4973-84. doi: 10.3390/ijms16034973. Review.

17.

[ABC proteins as molecular targets for drug discovery].

Kobayashi A, Kimura Y, Matsuo M, Ueda K.

Nihon Yakurigaku Zasshi. 2005 Apr;125(4):185-93. Review. Japanese. No abstract available.

PMID:
15930794
18.

Novel treatment targets for cerebral edema.

Walcott BP, Kahle KT, Simard JM.

Neurotherapeutics. 2012 Jan;9(1):65-72. doi: 10.1007/s13311-011-0087-4. Review.

19.

Glibenclamide in cerebral ischemia and stroke.

Simard JM, Sheth KN, Kimberly WT, Stern BJ, del Zoppo GJ, Jacobson S, Gerzanich V.

Neurocrit Care. 2014 Apr;20(2):319-33. doi: 10.1007/s12028-013-9923-1. Review.

20.

Effect of glibenclamide on the prevention of secondary brain injury following ischemic stroke in humans.

Khanna A, Walcott BP, Kahle KT, Simard JM.

Neurosurg Focus. 2014 Jan;36(1):E11. doi: 10.3171/2013.10.FOCUS13404. Review.

Supplemental Content

Support Center